MedPath

This is a trial for the glioblastoma patients after surgery. It compares the short course of radiotherapy with short course radiotherapy and temozolomide after surgery. Comparison between two arms will be done in terms of overall survival, progression free survival and quality of life.

Phase 3
Completed
Conditions
Health Condition 1: null- Histopathologically confirmed newly diagnosed Glioblastoma, WHO grade IVHealth Condition 2: C719- Malignant neoplasm of brain, unspecifiedHealth Condition 3: C719- Malignant neoplasm of brain, unspecifiedHealth Condition 4: G89-G99- Other disorders of the nervous system
Registration Number
CTRI/2018/07/014931
Lead Sponsor
Post Graduate Institute of Medical Education and Research Chandigarh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
70
Inclusion Criteria

1. Histopathologically confirmed newly diagnosed Glioblastoma(GBM), WHO grade IV.

2. Age and KPS (Appendix I) criteria:

i)>=65 years old and KPS score of 50-100.

ii)50 to 65 years old and KPS score of 50-70.

Exclusion Criteria

Patients who have received prior chemotherapy or radiotherapy.

Patients not willing to complete the quality of life questionnaires.

Other co-morbidities like diabetes, hypertension, etc. not controlled with medications

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Overall Survival <br/ ><br>2. Progression free survivalTimepoint: 6 months
Secondary Outcome Measures
NameTimeMethod
quality of life assessmentTimepoint: 1 month post radiotherapy,3 months post radiotherapy and 6 months post radiotherapy
© Copyright 2025. All Rights Reserved by MedPath